Apellis stock jumps nearly 8% as investors look to JPM healthcare update

7 January 2026

New York, Jan 7, 2026, 12:14 PM EST — Regular session

Apellis shares were up about 8% midday, building on a volatile start to the year for biotech stocks
The company is due to present at the J.P. Morgan Healthcare Conference on Jan. 12
Investors are watching for any commercial and pipeline updates on Syfovre and Empaveli

Apellis Pharmaceuticals shares rose nearly 8% on Wednesday, outperforming the broader market as traders positioned ahead of the company’s scheduled appearance at next week’s J.P. Morgan Healthcare Conference. Apellis

The Waltham, Massachusetts-based drugmaker said on Monday it will present on Jan. 12 at 11:15 a.m. PT, with a live webcast posted to its investor site and a replay available afterward. Big healthcare conferences often bring fresh guidance, new trial details or partnering chatter — and the tape tends to price that in early. Apellis

Apellis was last up $1.91 at $25.85 in midday trading, after touching $25.89. The stock opened at $24.02 and traded as low as $24.05, according to market data.

The company markets Syfovre, an eye injection for geographic atrophy — an advanced form of age-related macular degeneration that can lead to irreversible vision loss — and Empaveli for a rare blood disease called paroxysmal nocturnal hemoglobinuria. Competitive pressure and demand trends for Syfovre have been the key swing factors for the stock over the past year. BioPharma Dive

Apellis also posted recent insider reporting to the SEC, including Form 4 filings tied to equity awards. Those filings are common in early January and do not necessarily signal a change in executives’ views, but they can draw attention when a stock is moving. Apellis

What investors are watching next is simple: whether Apellis uses the JPM stage to sharpen its outlook on demand for Syfovre, update payor access and safety monitoring, or outline next steps for its pipeline. Any shift in tone — even without new numbers — can move a name that’s been this headline-sensitive. Apellis

There’s a clear “but” for bulls: the geographic atrophy market is competitive, and Syfovre’s uptake has been scrutinized closely since launch. Any sign of slower prescriptions, tougher reimbursement, or safety worries resurfacing could cap the rally quickly. BioPharma Dive

Shan Ahmed Khan Latest posts

As a journalist focused on finance and the stock market, he delivers fast, reliable, and easy-to-understand coverage of market news.

View all

OVT.AX Ovanti Ltd jumps 50% on ASX on Jan 8, 2026 on volume surge
January 8, 2026, 7:07 AM EST. OVT.AX Ovanti Ltd jumped 50% to A$0.003 on 08 Jan 2026, on volume of 78,494,817 shares, above the 50-day average and well above the prior close. The session traded A$0.002-A$0.003, with liquidity topping its average of 58,534,946. The price remains below the 50-day moving average of A$0.00463, signaling only a short-term momentum spike, not a reversal of the longer-term downtrend (200-day avg A$0.00548). Meyka AI assigns a 65.55/100 score and HOLD; its forecast shows a monthly target near A$0.01000 and a 12-month projection around A$0.00338. Fundamentals show revenue per share A$0.00131 and negative EPS of A$-0.01; market cap about A$14.84 million with 4.95 billion shares outstanding. Tech sector, IT services; RSI 42.8, ADX 30.99; MFI 32.5.